Cabenuva injection is a 2-drug co-packaged product that combines cabotegravir, an HIV integrase strand transfer inhibitor, and rilpivirine, an HIV non-nucleoside reverse transcriptase inhibitor. The ...

Simultaneous approval of VOCABRIA (cabotegravir oral tablets), for short-term treatment in conjunction with CABENUVA (cabotegravir and rilpivirine extended-release injectable suspensions), also ...

The approval of Cabenuva was based on data from two phase 3 trials which included 1182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) prior to initiation. The ...

People with HIV may have to take multiple medicines just to keep the virus under control. Medicines for HIV are usually taken every day, and it is crucial that people do not miss their dose or else ...

Cabenuva is administered as two separate injections into the gluteal muscle by a healthcare professional to treat HIV in adults and in children 12 years and older who weigh at least 77 pounds. The ...

(Reuters) - The U.S. Food and Drug Administration on Thursday approved a long-acting HIV injection from British drugmaker GlaxoSmithKline's HIV treatment division, ViiV Healthcare. "This is the first ...

Cabenuva is a prescription medication used to treat HIV in certain adults and children by reducing the amount of HIV in the body. It is given as an injection by a healthcare professional, either ...

Add Yahoo as a preferred source to see more of our stories on Google. A GSK logo is seen at the GSK research centre in Stevenage (Reuters) - GlaxoSmithKline's HIV treatments division has received ...

Cabenuva, an injectable medication for HIV, may cause both mild and serious side effects. More common side effects include fever, headache, fatigue, nausea, and injection site reactions. Serious but ...

Last week, the FDA denied the approval of Cabenuva, the first of its kind monthly HIV injection treatment. Developers hoped that the monthly injection would replace daily pills, thus making life ...

A kit with two injectable medicines—ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine— CABENUVA was co-developed as part of a collaboration with Janssen and builds on ViiV Healthcare’s industry ...

Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year ...